Cellectar Biosciences (CLRB) Capital Expenditures (2011 - 2024)
Cellectar Biosciences (CLRB) posted Capital Expenditures of $61286.0 for Q4 2024, up 188.05% sequentially from $21276.0 in Q2 2024, and down 77.03% YoY from $266756.0 in Q1 2024.
Cellectar Biosciences (CLRB) Capital Expenditures (2011 - 2024) Analysis & Trends
Cellectar Biosciences has reported Capital Expenditures for 14 years, with the latest figure at $61286.0 in Q4 2024.
- Quarterly Capital Expenditures fell 77.03% year-over-year to $61286.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $104195.0 (down 77.48% YoY) and the FY2025 annual result came in at $5880.0, down 94.36% from the prior year.
- Capital Expenditures rose to $61286.0 in Q4 2024 per CLRB's latest filing, from $21276.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $266756.0 in Q4 2023 and troughed at $4063.0 in Q3 2021.
- A 5-year average of $61005.9 and a median of $30070.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2024: Capital Expenditures jumped 653.86% in 2021, then plunged 77.03% in 2024.
- Over 5 years, Capital Expenditures stood at $17210.0 in 2020, then surged by 653.86% to $129739.0 in 2021, then declined by 9.16% to $117856.0 in 2022, then soared by 126.34% to $266756.0 in 2023, then slumped by 77.03% to $61286.0 in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered $61286.0, $21276.0, and $21633.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 251.02 Mn |
| 10 | Cellectar Biosciences | 6.78 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61,286.00 |
| Dec 31, 2024 | 61,286.00 |
| Jun 30, 2024 | 21,276.00 |
| Jun 30, 2024 | 21,276.00 |
| Mar 31, 2024 | 21,633.00 |
| Mar 31, 2024 | 21,633.00 |
| Dec 31, 2023 | 266,756.00 |
| Dec 31, 2023 | 266,756.00 |
| Dec 31, 2022 | 117,856.00 |
| Dec 31, 2022 | 117,856.00 |
| Sep 30, 2022 | 7,066.00 |
| Sep 30, 2022 | 7,066.00 |
| Jun 30, 2022 | 70,979.00 |
| Jun 30, 2022 | 70,979.00 |
| Mar 31, 2022 | 30,070.00 |
| Mar 31, 2022 | 30,070.00 |
| Dec 31, 2021 | 129,739.00 |
| Dec 31, 2021 | 129,739.00 |
| Sep 30, 2021 | 4,063.00 |
| Sep 30, 2021 | 4,063.00 |